Skip to main content
Premium Trial:

Request an Annual Quote

Astute Medical Raises $13M for Protein Biomarker Dx Development


Protein biomarker firm Astute Medical said this week that it has secured $13 million in financing.

The funding is an extension of a $26.5 million Series B round completed in May 2010 (PM 5/14/2010). The company also raised $6.2 million in a Series A round in 2008.

The $13 million financing included existing investors Domain Associates, Delphi Ventures, De Novo Ventures, and Johnson & Johnson Development.

Astute said it will use the money to advance and expand research, development, and validation of protein biomarker-based laboratory tests. According to the company, its focus is hospital- and community-acquired conditions that require rapid diagnosis and risk assessment.

In November, it received $244,479 through the Qualifying Therapeutic Discovery Project Program to be used for the development of a biomarker panel for the early detection of acute kidney injury (PM 11/5/2010).

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.